1. Academic Validation
  2. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies

Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies

  • Mol Pharm. 2015 Jun 1;12(6):1762-73. doi: 10.1021/mp5007757.
Wayne Widdison 1 Sharon Wilhelm 1 Karen Veale 1 Juliet Costoplus 1 Gregory Jones 1 Charlene Audette 1 Barbara Leece 1 Laura Bartle 1 Yelena Kovtun 1 Ravi Chari 1
Affiliations

Affiliation

  • 1 ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States.
Abstract

Several antibody-maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In preclinical studies in mice, the cytotoxic metabolites initially formed in vivo are further processed in the mouse liver to give several oxidized metabolic species. In this work, the primary AMC metabolites were synthesized and incubated with human liver microsomes (HLMs) to determine if human liver would likely give the same metabolites as those formed in mouse liver. The results of these HLM metabolism studies as well as the subsequent syntheses of the resulting HLM oxidation products are presented. Syntheses of the minor impurities formed during the conjugation of AMCs were also conducted to determine their cytotoxicities and to establish how these impurities would be metabolized by HLM.

Keywords

ADC; DM1; DM4; antibody; conjugate; drug; liver; maytansinoid; metabolism; microsome.

Figures
Products